Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

LY3015014

LY3015014: Another PCSK9 monoclonal enters the arena

LY3015014: Another PCSK9 monoclonal enters the arena

Hot on the heels of alirocumab, evolocumab and bococizumab, comes the next PCSK9 monoclonal antibody, LY3015014. In this aaleport, dosing every 4 weeks with LY3015014 resulted in about 50% reduction in LDL cholesterol, comparable to that observed with these other monoclonal antibodies. LY3015014 is a…

read more »